Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology

Special paper

Roman Nowicki, Magdalena Trzeciak, Aleksandra Wilkowska, Małgorzata Sokołowska-Wojdyło, Hanna Ługowska-Umer, Wioletta Barańska-Rybak, Maciej Kaczmarski, Cezary Kowalewski, Jerzy Kruszewski, Joanna Maj, Wojciech Silny, Radosław Śpiewak, Andriy Petranyuk

Postep Derm Alergol 2015; XXXII (4): 239–249

DOI (digital object identifier): 10.5114/pdia.2015.53319

Abstract: Atopic dermatitis (AD) is a condition frequently encountered in medical practices across the country. More than 60% of children with AD are at risk to develop allergic rhinitis or asthma (the atopic march). Patients with AD have a unique predisposition to colonization or infection by Staphylococcus aureus. Treatments for AD need to rapidly control symptoms of the disease, improve quality of life and prevent exacerbations. Given the chronic and relapsing nature of the disease, therapies need to encourage good compliance and be well tolerated.

keywords: atopic dermatitis, treatment, emollients, cosmeceuticals, topical corticosteroids, topical calcineurin inhibitors, antihistamines

View full text